*仅供医学专业人士阅读参考最近这段时间，大家都被变幻莫测的初春天气折腾到够呛吧？至少奇点糕记忆里之前就没在3月初看到过大雪纷飞，超大的早晚温差也让穿衣服成了棘手难题。天气能忽冷忽热来回切换，但人体内的肿瘤免疫微环境就没这么容易改变了，像某些出名的免疫 ...

人粒细胞巨噬细胞集落刺激因子（Granulocyte-Macrophage Colony-Stimulating Factor, GM-CSF）是一种关键的造血生长因子，能够促进粒细胞和巨噬细胞的增殖、分化与活化，在免疫调节、炎症反应以及肿瘤微环境中发挥重要作用。其浓度的精准检测对研究感染性疾病、自身 ...

Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as Colony Stimulating Factor 2 (granulocyte-macrophage), is a cytokine originally identified for its role in promoting the ...

研究人员评估 FMPV-1/GM-CSF 疫苗在健康受试者中的安全性和免疫原性，发现其耐受性良好且能诱导免疫反应，为相关癌症治疗提供依据。 一、研究背景 癌症，这个人类健康的 “头号杀手”，一直以来都让无数患者和家属陷入绝望的深渊。在众多癌症类型中 ...

点击蓝字关注我们【导读】免疫检查点阻断疗法（ICB）给癌症治疗带来了革命性的变化，但治疗反应却具有高度异质性，这凸显了开发预测性生物标志物和克服ICB耐药性的必要性。2025年3月17日，中国医学科学院肿瘤医院的研究团队在期刊《Signal ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the ...

文章强调了通过靶向肿瘤内在特征（如S100A1）来重塑TME，增强免疫治疗效果的潜力，并提出了GM-CSF与ICI联合治疗作为一种新型免疫治疗策略的可能性。 越来越多的证据表明，肿瘤细胞通过改变Ca2+稳态促进多种恶性生物学行为，如肿瘤生存、增殖和免疫逃避等。

Memorial Sloan Kettering Cancer Center, New York, New York, United States ...

The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been ...

Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...